Literature DB >> 19032230

Health economics of asthma: assessing the value of asthma interventions.

J D Campbell1, D E Spackman, S D Sullivan.   

Abstract

The aim of this systematic review was to summarize and assess the quality of asthma intervention health economic studies from 2002 to 2007, compare the study findings with clinical management guidelines, and suggest avenues for future improvement of asthma health economic studies. Forty of the 177 studies met our inclusion criteria. We assessed the quality of studies using The Quality of Health Economic Studies validated instrument (total score range: 0-100). Six studies (15%) had quality category 2, 26 studies (65%) achieved quality category 3, and the remaining eight (20%) studies were scored as the highest quality level, category 4. Overall, the findings from this review are in line with the Global Initiative for Asthma clinical guidelines. Many asthma health economic studies lacked appropriate long term time horizons to match the chronic nature of the disease and suffered from using effectiveness measures that did not capture all disease related risks and benefits. We recommend that new asthma simulation models: be flexible to allow for long term time horizons, focus on using levels of asthma control in their structure, and estimate both long term asthma specific outcomes like well-controlled time as well as generic outcomes such as quality adjusted survival.

Mesh:

Substances:

Year:  2008        PMID: 19032230     DOI: 10.1111/j.1398-9995.2008.01888.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  12 in total

1.  Community Health Worker Home Visits for Medicaid-Enrolled Children With Asthma: Effects on Asthma Outcomes and Costs.

Authors:  Jonathan D Campbell; Marissa Brooks; Patrick Hosokawa; June Robinson; Lin Song; James Krieger
Journal:  Am J Public Health       Date:  2015-08-13       Impact factor: 9.308

Review 2.  Cost-consequence analysis of multimodal interventions with environmental components for pediatric asthma in the state of Maryland.

Authors:  Mandeep S Jassal; Gregory B Diette; David W Dowdy
Journal:  J Asthma       Date:  2013-05-09       Impact factor: 2.515

Review 3.  Economic Evidence for US Asthma Self-Management Education and Home-Based Interventions.

Authors:  Joy Hsu; Natalie Wilhelm; Lillianne Lewis; Elizabeth Herman
Journal:  J Allergy Clin Immunol Pract       Date:  2016-09-19

4.  Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review.

Authors:  Carlos E Rodriguez-Martinez; Monica P Sossa-Briceño; Jose A Castro-Rodriguez
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

5.  Cost-effectiveness analysis of corticosteroid inhaler devices in primary care asthma management: A real world observational study.

Authors:  Linda Kemp; John Haughney; Neil Barnes; Erika Sims; Julie von Ziegenweidt; Elizabeth V Hillyer; Amanda J Lee; Alison Chisholm; David Price
Journal:  Clinicoecon Outcomes Res       Date:  2010-07-01

Review 6.  Economic evidence on the health impacts of climate change in europe.

Authors:  Guy Hutton; Bettina Menne
Journal:  Environ Health Insights       Date:  2014-11-03

7.  Economic evaluation of enhanced asthma management: a systematic review.

Authors:  Yee V Yong; Asrul A Shafie
Journal:  Pharm Pract (Granada)       Date:  2014-03-15

Review 8.  Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.

Authors:  Simon van der Schans; Lucas M A Goossens; Melinde R S Boland; Janwillem W H Kocks; Maarten J Postma; Job F M van Boven; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

9.  Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.

Authors:  Tomoyuki Takura; Takashi Takei; Kosaku Nitta
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

10.  Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.

Authors:  David Yamamoto; Jonathan D Campbell
Journal:  Autoimmune Dis       Date:  2012-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.